Thank you, operator, and thank you everyone for joining us here today. I'm joined by the Novozymes management team and the rest of our investor relations team. My name is Tobias Björklund and I'm the head of investor relations. Yesterday, we released our full-year interim report for the first half of 2020 after having pre-announced our sales and preliminary EBIT margin on July 8th. At this call, we will review our performance and key events from the first six months of the year. The call will take around 50 minutes, including time for questions. Before we begin, I would like to remind you that the information presented at this call is unaudited, and that management may make forward-looking statements. These statements are based on current expectations and beliefs, and they involve risks and uncertainties that could cause actual results to differ materially from those described in any forward-looking statements.
With this introduction, I will now hand you over to our CEO, Ester Baiget. Ester, please.
Thank you. Thank you, Tobias, and thank you all for calling in. As you all know, we announced our sales and preliminary EBIT for the first six months of 2020 on July 8th. Therefore, the focus of today's call will be on a review of our full financial performance for the first half of the year, as well as the restated full-year outlook for 2020. During the first half of the year, our main priorities were to ensure the safety of our employees and the continuity of our services to our customers and supply chain partners. I am proud to say that we succeeded in that effort, while also delivering on sales, earnings, and cash flows. We continue to progress on the projects in our innovation pipeline.
In the second quarter, we launched five exciting products, and we continued the commercialization of our recently launched solutions, such as Freshness in Household Care, and Balancius in animal feed. In other words, our innovation machine is running close to full throttle, and even in these unprecedented conditions, we are introducing high performance and sustainable solutions to the world. As societies carefully reopen across the world, we have decided to restate the outlook for 2020. Before we dive deeper into that, let me spend a few minutes on our performance for the first six months of the year. Could you please turn to slide number 2? In the first half of the year, the business was both positively and negatively impacted by events related to the COVID-19 pandemic.
Changing consumer behavior, such as stockpiling, increased focus on personal hygiene, and more at-home food consumption, had a positive impact on both our Household Care, and food-related businesses. At the same time, stay-at-home orders and social distancing had a significant negative impact on our bioenergy, beverages, and textile businesses. Overall, we delivered a solid set of numbers in the first half of 2020. Total sales grew organically by 4%, with strong cash flows and solid earnings. Agricultural and feed grew organically by 17%, Household Care by 11%, and food and beverages delivered 7% growth. At the opposite end of the spectrum, technical and pharma and bioenergy declined by 22% and 15%, respectively. Looking at the second quarter performance, sales declined by 2% organically, which is sound considering the severe headwinds in the U.S. ethanol market and the textile global industry.
We delivered a healthy first half EBIT margin at 27.5%, a strong free cash flow before acquisitions of 2.1 billion DKK. As countries and economies carefully reopen, Novozymes now reinstate its full-year 2020 outlook. We expect an organic sales performance of -2% to +2%, with the development in the U.S. ethanol industry being the main source of uncertainty. Lars, we'll go later in the call through the details of the full financial outlook a bit later. Please turn to slide number three. In the first half, organic sales in emerging markets grew by 9%, and developed markets grew by 1%. Growth was broad based across all major regions except North America, where the severe decline in the U.S. ethanol production had a significant negative impact on overall growth in developed markets.
The decline in the North American bioenergy businesses was the main reason for the second quarter organic decline of 5% in developed markets. Sales in emerging markets grew 4% in the quarter, primarily driven by Household C are, but somehow hampered by the development in the textile businesses. Could you please turn to slide number four? Thank you. Sales in Household Care grew by 11% organically in both the first half and the second quarter of 2020. The strong sales performance was led by increased enzymatic penetration of laundry and dishwashing detergents, the continued rollout of the Freshness platform, as well as the COVID-19 induced stockpiling and changes to the consumer behavior. COVID-19 related stockpiling continued from March into April, but eased through the end of the quarter. On the innovation front, we launched our first enzymatic solution for cleaning medical and surgical instruments and devices.
This is a very interesting and relevant area, with more exciting projects in the pipeline. Looking ahead, enzymatic penetration into more detergents, especially in the emerging markets, and the rollout of Freshness will continue to drive growth. However, the destocking by both the customers and the consumers is expected to hamper growth in the second half. If we move into slide five. Food and beverages sales in the first half grew by 7% organically. The sales performance was led by strong growth in baking, followed by solid results in both starch and food and nutrition, while beverages declined slightly. Sales of enzymes for food production benefit from more at-home consumption due to the COVID-19, where enzymes for beverages, especially for brewing, were impacted negatively by the lower on-trade demand.
In the second quarter, the sales of food and beverages grew 3% organically, with positive contributions from baking and food and nutrition offsetting the decline in beverages. Starch sales were flat in the second quarter. On the innovation front, food and beverages delivered two new solutions in the second quarter, Quara Boost and Protana Prime. Quara Boost increases the yield of vegetable oil processes by retaining oil that is usually wasted in the gum fraction. Protana Prime enables tastier meat alternatives by the extraction of the natural flavor from plant proteins. Looking ahead, the positive effects of increased at-home food consumption are expected to ease, while beverages will likely still be affected by the COVID-19 related restrictions. Please turn to slide six. Bioenergy sales in the first half of the year declined by 15%, as COVID-induced stay-at-home restrictions severely disrupted U.S. demand from ethanol in March and onwards.
This resulted in a 13% decline in global organic sales for bioenergy in the second quarter. The U.S. production rates improved towards the end of the quarter from the lows in April and May. Outside of North America, the expansion of starch-based ethanol capacity in Brazil generated a minor positive sales contribution in the second quarter, while sales to the European producers declined. We still believe there is a high level of uncertainty to the production levels for U.S. and the global ethanol volume for the remainder of the year. Please turn to slide seven. Sales in agricultural and feed grew 17% organically in the first half, and 20% in the second quarter. Both feed and ag bio businesses contributed to growth in the first half and the second quarter.
The feed businesses performed well in the second quarter, likely supported by the inventory changes in the value chain. This was also seen in the first quarter. Organic growth for the BioAg business was positively impacted by one-off settlement related to the former BioAg setup. Adjusted for this factor, agricultural and feed would have still posted healthy double-digit organic sales growth in the second quarter. Looking at the full-year, we expect continued penetration of Balancius, our inoculants for corn and Taegro, all contributing to growth. However, global farm economics, trade economics, and COVID-19 continue to be sources of uncertainty for the businesses. Organic sales in technical and pharma declined by 22% in the first half and 34% in the second quarter.
The decline was due to COVID-19-related impacts on the apparel and textile industry, as well as the continuation of last year's decline in Chinese textile production. With that, I will hand it to our CFO, Lars.
Thank you, Ester. Please turn to slide eight. Organic sales declined by 2% in the second quarter. Was up by 4% for the first six months of 2020. Household Care and Agriculture and Feed posted strong double-digit growth in the first half, while our Bioenergy and Technical and Pharma declined significantly. We delivered a solid set of financials despite the very challenging conditions. The gross margin was up by 120 basis points to 56.3% in the first half. The improvement was driven by higher operational leverage, improved production efficiencies, as well as slightly lower input costs compared to 2019. The gross margin of 55.4% in the second quarter benefited from a one-off settlement related to the former BioAg setup.
The first half EBIT margin was 27.5%, or 250 basis points lower than for the same period of last year, as the 2019 EBIT margin was supported by the recognition of deferred income related to the termination of the former BioAg Alliance and proceeds from the divestment of a pharma-related royalty. Excluding one-offs in both 2019 and 2020, the EBIT margin grew roughly 200 basis points from around 25% in the first half of 2019 to an underlying EBIT margin of roughly 27% in the same period of 2020. This corresponds to double-digit growth in underlying EBIT. The improvement from 2019 to 2020 was mainly driven by increased gross profit, as well as hiring and travel-related savings. The return on invested capital, including goodwill, was 19.3% in the first half of 2020. This was 260 basis points lower than for the same period of 2019.
The ROIC declined due to both higher average invested capital and the lower net operating profits after tax. The average invested capital in 2019 benefited from the deferred income related to the now terminated BioAg Alliance. Together with the acquisition of PrecisionBiotics Group in 2020, these were the main explanations of the increase in average invested capital from 2019 to 2020. The net operating profits after tax declined due to the lower reported EBIT from the non-recurring income in 2019. Net investments excluding acquisitions were DKK 364 million in the first half of 2020. This was slightly less than for the same period of 2019. Our free cash flow before acquisitions was DKK 2,051 million in the first six months. This was DKK 833 million higher than for the same period of 2019.
The strong improvement was mainly due to higher sales, gross margin expansion, savings on operating expenses, and improved net working capital. In the second quarter, cash flows also benefited from the BioAg settlement and a postponement of tax payments from the second to the third quarter of 2020. Please turn to slide nine for the reinstated 2020 outlook. After careful consideration, we have decided to reinstate the full-year outlook for 2020. We expect an organic sales performance from -2 to +2 in 2020. Organic sales in household care, food and beverages, and agriculture and feed are expected to deliver solid mid-single-digit growth, while bioenergy and technical and pharma are subject to the most uncertainty in terms of full-year performance.
In the scenario of a 2% decline in organic sales, we assume sales in bioenergy will decline significantly more in the second half than the 15% decline seen in the first half. Sales in technical and pharma would continue to decline severely. In the scenario of a 2% organic sales growth, we assume that the decline in U.S. ethanol production will be more in line with the current EIA outlook of around 12%, and that the pressure on our technical business will ease. The full-year EBIT margin expectation is lowered to around 26% from around 27% in January. Gains from productivity improvements and cost controls are expected to be outweighed by negative effects from deteriorating currencies, lower operational leverage, and added amortization from the acquisition of PrecisionBiotics.
The outlook for ROIC, including goodwill, is expected at 18% - 19%, which is two percentage points lower than the outlook from January. This is due to lower sales, lower EBIT margin, negative impact from currencies, and the negative effects from the PrecisionBiotics acquisition on both net operating profits after tax and the invested capital. Finally, free cash flow before acquisitions is expected at between DKK 2.4 billion and DKK 2.8 billion, reflecting a good underlying cash generation. With this walkthrough of the financials and our reinstated outlook, I'll pass the word back to Ester.
Thank you, Lars. If we could please turn into slide 10. Let me summarize our key messages. In the first half, we delivered solid results by being there for our customers. We launched five new products, and most importantly, we work to ensure the safety of our employees. As countries and economies carefully reopen, we now provide a full-year 2020 year outlook with an expected organic sales performance of -2% to +2%. We believe the wide range is the right approach, considering the turmoil and high volatility in the U.S. ethanol industry. While conditions are challenging, the agility and the resilience of the business demonstrate that we are on the right track to deliver more value with innovative and sustainable solutions for better lives in a growing world. We are executing on the strategy with a clear prioritization-driven agenda, both commercially and in R&D.
This has most recently been exemplified by the acquisition of PrecisionBiotics, adding to our promising human health alternatives. As a final remark, I'm very proud of the commitment and dedication of our colleagues during these challenging times, and to them, I would like to thank and extend my sincere gratitude. I would also like to say thank you for listening to our call this morning. We're now ready to take your questions.
Thank you. First question comes from the line of Jonas Guldborg of Danske Bank. Please go ahead. Your line is open.
Yeah, thank you, good morning, all, and thank you for taking my questions. First question on organic growth. You say it's down 5% in developed markets in Q2, primarily due to Bioenergy in the U.S. What was the growth in developed markets excluding this U.S. ethanol? Then I also guess that the fact that you are stating that July is showing negative growth is mainly due to Bioenergy, but how much is July actually down? I'm talking low single digit or mid-single digit or what, and specifically is household care down in July? My second question is on currencies. You are expecting or guiding for a significant negative impact in H2 on revenue.
I was just thinking, how is this filtering through to gross profit and EBIT, and is there also a spillover effect on H1 next year as well? My third question is on the reinvestments. How large a part of the DKK 250 million you plan to reinvest in the business in 2020 has been reinvested here in H1? How much do you expect to reinvest in 2020? Still 250, or have you reduced that number? Thank you.
Lars.
Thank you. Thank you, Jonas. First question on the organic growth. When you say that we are down by 5% in the developed markets, including bioenergy. Without the bioenergy, that's probably on the opposite side of, you could say zero. That's probably like the +5% level. I think when you take and isolate the bioenergy decline, then that has that impact of changing it from -5% to +5%, roughly, in big numbers. If you look at July, what we say is slightly negative, and we are not giving details on the individual divisions. We are giving that as a comfort that we are looking, you can say, to deliver on the -2% to +2% for the year.
If you look at bioenergy specifically, there is a correlation between the external numbers of production that you see in the external statistics and our numbers. Of course, it's not a full 100% correlation. There is a correlation, and that will give you an indication of where bioenergy is also in July. When you look at currencies, we have provided a guidance or a separation of currencies in our stock exchange announcement, and has done that for years. You will see in there that roughly one third of our sales is denominated in US dollar. Obviously, it's very transparent what the US dollar is and what it means, both on sales and also on EBIT. What is harder to assess and calculate is the impact from emerging market currencies.
If you look at our sales distribution, you'll see that roughly 25%, if you exclude China, is sold in Asia Pacific, Latin America, Middle East, and Africa. When you look at the graph we have in the stock exchange announcement on currency, you'll see that 13% of the sales is denominated in currencies outside of EUR, USD, the CNY, and DKK. Roughly half of that sales therefore is invoiced in hard currencies. The other half is invoiced in local currencies. You see currencies like the Brazilian real, which has depreciated by 24% on average between 2019 and 2020. You see other emerging market currencies like the Russian ruble, the Argentinian peso, and others that has also decreased and devalued quite substantially. That's why and that's how the impact on the top line is derived.
How will that spill over to the EBIT margin and the gross margin? Because we have more, relatively speaking, of our costs denominated in hard currencies, and in particular the DKK than we have our sales, you can say that it has a negative impact on the margin. That's what we're calling out. The vast majority of the difference between 27% guidance in January and 26% guidance now is related to currency. A little bit to the impact from our acquisition of PrecisionBiotics, as we also shared with you in June. Whereas for other items, we are really, you can say, balancing or offsetting the lower leverage on the gross margin from a lower midpoint of our sales with savings on our operational expenses and postponed investments, like we've also said all the year. Those two or three components are offsetting each other.
To your last question, how much are the reinvestments? We have not been able to effectively invest the full DKK 250 million or so this year. We are probably pushing something like half of it in front of us, and have included roughly half of it in our outlook. Of course, as time goes by, it becomes harder and harder to separate what is a saving on not filling a replacement and what is sort of a specific investment in expansion. I would say, if you sort of consider it in the big terms, that roughly half of the total release of resources last year, we expect in our guidance to be able to spend and also spend effectively with investments picking up in the second half. I hope that answer your questions.
Sure did. Very helpful. Thank you very much, Lars.
Thank you. Our next question comes from the line of Matthew Yates at Bank of America. Please go ahead. Your line is open.
Hey, good morning. I've got two questions, please. The first is just a clarification on the BioAg and Feed business. I think your full-year guidance is around a mid-single digit growth. Can I just check, does that include the significant one-off that you had in Q2? Can you give us a little bit more color on the severity of the destock that you're seeing in Q3? The second question is just a follow-up on the prior gentleman around the margin, and I'm interested in your thoughts going into 2021. You explained the impact of foreign exchange there on the revised guidance. In terms of the cost base, if you've only made half the planned reinvestments next year, should we assume that you still intend to make the other half? In light of the weaker volume development, are you revisiting those plans on the cost side?
Thanks very much.
Tina, if you could take the question and the guidance from BioAg and Feed and Lars on margins, please.
Yeah. On Ag and Feed, we in Q2 report 27% growth, and roughly 15% of that is due to the agriculture one-off. That means that if you look at the half year, we grew 17%, if you correct for the one-off we had in Q2, we will get into the high single digit for the half year without that one-off. That also means that when you look at, we are saying the mid single digit growth for the full-year, yes, that do include the one-off. We are looking at some de-stocking in feed. We know the inventory level of our alliance partner, you would also be able to see from the reporting of our alliance partner that they have also been out talking about stocking in the value chain.
You have to remember that roughly two-thirds of sales in Ag and Feed comes from the feed part, and roughly a third comes from the ag part. We still believe that there are uncertainty ahead of us in ag. That's due to farm economics, and we are also ahead of the Brazilian planting season, which we have ahead of us. Well, though we do still see innovation continue to penetrate both, as Ester was alluding to before, with the corn inoculants, with Taegro, and also with Balancius.
Thanks, Tina. On the margin, yes, we are still committed to invest what we released of resources last year in support of accelerated growth towards the five plus percent we have shared as our long-term financial targets towards 2022. Specifically for 2021, then of course, the actual margin that we will record in 2021 will be a result of the leverage we get from hopefully growing again in 2021. With these investments to support that growth offsetting, then we will have to see where our currency is at the time. I think you should still think about our development in margin towards the 28% margin we have set as the long-term target at the end of 2022. Those were set, I'll just remind you, based on the level of currencies we had at the time of release in June of last year.
We will see where those currencies are at the end of 2022. The underlying fundamentals are unchanged, and we are still committed to invest to accelerate our growth.
Thanks for taking the questions.
Thank you. Our next question comes from the line of Michael Novod at Nordea. Please go ahead. Your line's open.
Thanks a lot. Yes, Michael from Nordea. Just two short questions. Just going back to the comment on July, I know you're not going to give any major details, but also just to figure out whether July last year was sort of a strong July, a soft July, a normal July. Whether what you see in your July numbers, whether the slight decline is what you sense being mainly de-stocking or what is going on, or whether it's more sort of the fundamentals of the market. Secondly, maybe if you just elaborate a bit more on how you see a potential recovery in tech and pharma, given what we probably have ahead of us in the next 6-12 months in terms of a very tough environment globally in the economy.
Thank you. I will let Hannes further elaborate on the tech and pharma, but then to your specific question on July, last year was a strong July. That makes the comparison for the relative and the results that we're seeing today even probably stronger. It's important to mention that we have seen a high level of volatility in the past. We saw it in Q2, especially on bioenergy, where the sales drop, we saw a decline of higher than 30%. The signs that we see of a recovery, they are there, but we have also learned that it can change very fast and very rapidly. That's a driver, the main driver of the range that we're putting on the new guidance, the volatility and the uncertainty, specifically on bioethanol.
It is also true that in the first half of the year, specifically in Q1, we saw an increased demand because of stockpiling, both at our customers or the end user facilities from both detergents and changing consumer habits on food. We see the underlying dynamics of the demand and the consumers still there and continue to be there. We also see the strong penetration and commercialization of our innovation. We're foreseeing the de-stocking effect strongly on the second half than the one, and then that will be at the expenses of the pickup that we saw in the first one.
Thanks, Ester. On Tech and Pharma, we continue to be impacted in this business also full-year, we expect to see improvements over where we were in Q2, but not back to the levels of 2019. I think it's important to stress that it's mainly textile that's our issue here, you can follow what retailers are saying. When I look at the reports that's been coming out from Zara and H&M and Gap, they talk about 40%, 50% declines in their businesses, that does translate almost directly into our sales. They expect improvements, so do we.
Okay. Well, that was exactly my point, that it's difficult to see the major improvements going into the next six months of economic environment.
That's correct.
That's right.
Next question, please.
Thank you. Our next question comes from the line of Søren Samsøe of SEB. Please go ahead, your line is open.
Yes, good morning. Søren here from SEB. Just two questions from my side. In your guidance, the range of - 2 to + 2, maybe you could elaborate a little bit on how much de-stocking you have included in, you can say, each end of the range. That's the first question. The second question is, we've seen actually a significant surge in the corn prices in China recently. Would that impact your starch business in China negatively in the second half, do you think? If that's the case, how have you factored that into your guidance for second half? Thank you.
Lars, if you can take the first one, Andy, the question on starch.
Yeah. In terms of de-stocking, as we have said, there has been a component of stocking in the supply chain. In the beginning of the COVID period, that was very visible. Although we didn't have transparency of how much, in both household care and Food & Beverages. In second quarter, we have seen some of that stocking in the supply chain return, so to speak, in Food & Beverages. Whereas there is probably not so much of change during the quarter in household care. I would say in the upper end of the range, we would assume very little correction of the supply chain. Whereas if we are at the bottom, that would also imply somehow a recurrence of COVID. You could say in that end, there will probably not be a very significant impact from any change in the supply chain.
I think that's how you should look at it. Again, it's probably household care where it is most prevalent. We do, in our guidance, assume a bit of correction in the second half from what we have seen in the first half. Andy?
Yeah. On the starch side, I think one thing to note is that we had a pretty big order pattern related effect in the first quarter in China in starch, where we had really nice growth. Second quarter, we saw it slow down a little bit, but we're actually kind of ahead of where we expected to be. It's been a bit more robust than anticipated. I think for the back half of the year, we kind of expect it to stabilize at the higher corn price levels, and it's going to be somewhat related to how well the beverage industries perform.
We expect a bit of recovery, and that'll support starch processing.
Next question, please.
That comes from the line of Lars Topholm of Carnegie. Please go ahead, your line's open.
A couple of questions from me. Lars, one is just a follow-up. When you commented on the 28% margin target for the end of 2022, you pointed out that it was agreed upon in the summer of 2019 based on the exchange rates valid back then. Everything else equal, what would the 28% look like based on the exchange rates we have today? Ester, a question for you, because now you've been around for half a year. You have inherited a midterm growth target of more than 5% organic growth. You haven't changed it, does that mean you are happy with this target? If you are, maybe you can comment on which divisions will more than that and which will grow less.
If you are not happy with it, maybe you can share some thoughts on when this might be reviewed, if it's going to be reviewed at all. Thanks.
Thanks, Lars. I'll take the first question on the margin. I have to admit, I have not calculated with the current spot rates, what would it be in end of 2022 on our long-term guidance. I think what occupies me more is that the underlying improvement in our margin stays intact, and that we, through acceleration of growth, can continue to live a gross margin expansion, and that we actually allocate the resource and capital to invest in that acceleration of growth to succeed. I think that's where I have my focus. To answer your question specifically, I guess the impact of currency for this year is a good proxy for what the impact is since last year. Again, let's see where the currencies are at the end of 2022, and then that will give us the final answer.
To your question, Lars, on guidance, we will have to wait for the final answer on the guidance when we're coming with the new guidance for next year. What I can tell you for sure is that during these first six months, my first six months, we have been swiftly and firmly moving ahead with implementation of our strategy. That's across the whole areas. Through the prioritization and allocation of resources, of innovation in the areas that deliver the most, and focusing on the productivity and on the cash release on the areas that we see as the drivers of growth in those BPUs. Solid examples of the implementation of the strategy are the development, new launches that we have provided across all areas.
That's also a sign of the appetite of the world to the answers that we provide and to the breakthrough innovations to respond to the society needs. Another solid example is the penetration and the successful commercialization as we're seeing it in the supermarkets of Freshness, despite the challenging environments. Another example of the implementation of our strategy is the acquisition of PrecisionBiotics, where we set the platform and the foundation of growth for an area that we identified an strategic priority for us. In a growing world, I am very confident on the capability of us as a company to deliver sustainable earnings growth, and that's the commitment that we're getting from the team, and that's also the space that we're going to continue to work.
As we did in the first half, it's resilience, it's ductility, it's responding to the market needs and providing those questions into answers and moving firmly and strongly every day a little step.
I should interpret this as today you are happy with the more than 5% organic growth ambition until 2022?
In a growing world, when in an environment as in the way that it was set when we put the guidance, I'm fully confident on our capability to deliver. We have also learned, and we have seen that there is a volatile world, the one that we live in. We just reinstall guidance. That shows a sign of our confidence as we're learning and embracing the reality that we're living in. We're going to do the same when we come with a new guidance for the long term.
Okay. Thank you, Ester. Thanks for answering my questions.
Thank you. Our next question comes from the line of Anette Lykke of Handelsbanken. Please go ahead, your line is open.
Yes, thank you so much for taking my question. I want to go back to growth for household care, plus 11% both Q1 and Q2. To reach the mid-single growth, this means that it should be flattish. I assume this is primarily coming from a de-stocking effect. Can you tell us if you already saw that de-stocking effect in July? If we could share a little bit more on the components we have talked about that you have a better insight to what the components are behind the plus 11%. On the bioethanol, I suggest that the weekly production is indicating a negative of around 10% for July. That seems that you should be in the top end of your guidance. Do you agree on that, if this is something that would persist for the remainder of the year?
Then of course, how close are the correlation? I know it's not 1 - 1. Is it possible for you to increase your market share, or are you increasing market share in this declining market? What about the prices? That is my questions.
I will let Hans and Tina answer respectively.
Thanks for the question. Let me start out by answering the first household care question. Let me maybe start out by saying that we are very pleased with the sales performance in household care for the first half. Obviously, 11% is very strong. What drives this is a combination of a few things. First of all, we were building a good momentum in the second half of 2019, driven by Freshness in emerging markets that continued into the first half. We're very pleased with that. Then we got a bump up with some COVID related effects that relates to a few different things. One is stockpiling in the chain. It's both with consumers, it's in retailers, and it's with our customers.
We have also seen that some of our customers are now talking about more wash loads being done by consumers, and we've also seen a search towards higher quality detergents. That's the drivers for the 11%. That's also one of the reasons for us believing that we can't sustain that level, that some of that will be reversed, especially when it comes to the COVID related effects on stockpiling. The exact effect of that is difficult to estimate. In addition to that, we also had some very easy comps in the first half of 2020, and that of course does reverse as we get into much more difficult comps in the second half. You have to think about it this way, that last year, first half performance or second half performance was almost 10% higher than the first half performance.
That's of course the territory that we get into now. I hope that answers the question. Thanks.
On bioenergy, Anette. As you're saying, there isn't always a direct correlation between the behavior our customers are having and the EIA numbers. As Lars has alluded to earlier, it is a good indication. We also see that in our numbers and in our close interactions with our customers, that they are also starting to pick up. If you look at the first half of 2020. Our performance is roughly aligned with what it is that EIA have come out with. However, when we look ahead, you are right in that EIA is looking at a slight increase compared to where you are year to date in the EIA numbers. They are looking at moving from roughly around -15% to -11%, -12% for the full-year. They are looking at some increase in second half.
However, we do believe that there are uncertainty in the fuel area still. In the lower end of our guidance, we have included a worse situation than what it is that EIA is expecting, almost twice the decline as what it is you saw in first half. You also asked about what were the effects due to, I would say that the performance we have seen in the first half is due to less ethanol being produced. We see limited or hardly any share moves and limited effect of price mix. I hope that answers your question.
Okay. Thank you so much.
Our next question comes from the line of Sebastian Bray at Berenberg Bank. Please go ahead, your line is open.
Good morning, thank you for taking my questions. I would have two, please. The first one is on the ramp-up in Freshness sales. From memory at the outset of this product, a guidance of about DKK 1 billion was given per annum or an ambition. How far are we there? Are we currently at about a 40%-50% run rate as a rough guess? My second question is on the acquisition of PrecisionBiotics. Historically, Novozymes, I think, has had a ratio of roughly 10% microorganisms to 90% enzymes in sales. Is there any scope for this to shift in future? Thank you.
Hannes, if you can take the first question, then Thomas on the PrecisionBiotics, please.
Yeah. Thanks for the question. Maybe a few comments that I will make is that Freshness for Novozymes right now is still with Procter & Gamble only. We are on the plan that we set some years back with P&G, and that is actually being executed very well. If you follow what's happening on the commercial side of this, you can also see that they are out talking about technologies that relate to what we have developed with them. One thing is we are on target with P&G for the launch. The other one is that we are investing in other technologies for the broad market, and those are also coming along as we planned originally.
We are talking about a launch in the mid of 2022, where we expect to go out to the broad market with solutions in this space. Giving an exact number of where we are, we are not, but we are still committed to the 1 billion on Freshness.
When it comes to the acquisition, you're absolutely right that currently our business has a split of microbes around 10% and enzymes around 90. We are not operating on this ratio. This is just where we are. Looking at Novozymes, we have the toolbox of microbes and enzymes, and whenever we see opportunities in the marketplace, we are looking at the totality of our toolbox, not that it has to be one or the other, and that's actually one of the strengths. Within our One Health activities, we're also looking at enzymes, and within our more existing businesses, we are also looking at microbes. We will apply the total toolbox going forward.
Bear with me, there's a little bit of a follow-up.
Yeah. Sorry, I just want to correct that now for everybody on the call. It's mid 2021 that we come out with a broad market solution, not mid 2022. Sorry about that.
Understood. Thank you.
Thank you. The last question in the queue so far is from the line of Silke Kueck of JPMorgan. Please go ahead, your line is open.
Hi, how are you? I was wondering if you can discuss your organic growth performance in July on a regional basis. On slide four, you talk about your first quarter results and your first half results. I was wondering whether you can do something similar for your July sales. I was also wondering whether when you look at the first two weeks of August, I was wondering what you've seen so far. Thank you.
Thank you for this last question. We typically don't disclose results by the month, not by the week either. If anything, it is the sentiment that we're bringing in, it is that it's in alignment of what would be projected, then it's included in our forecast for the year. I'm going to repeat probably what it has been said during the call, that we are aiming for a solid mid-digit or single-digit growth for three of our businesses, for Household C are, for Food & Beverages, and for BioAg. Being a detergents or technical industry and BioAg, the drivers of highest level of uncertainty, especially on bioethanol, the highest driver of uncertainty, bioethanol, bioenergy. That's the poles that we're living in. We're seeing good signs, but we've also seen fast moves in the industry, and we've seen them fast.
As U.S. economy recovers, as the social distancing lifts, and as gasoline demand consumption increase, we will translate those opportunities into sales for our enzymes and make sure that we capitalize them to the bottom line. That's it.
Thank you. As there are no further questions at this time, I'll hand back for the closing comments.